As the 2026 Congress of the European Hematology Association (EHA 2026) prepares to open in Stockholm, Sweden, the global hematology community is once again gathering to share the latest scientific advances and shape the future of blood disease research and treatment.

The rapid emergence of CAR-T cell therapies and bispecific antibodies has transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM), leading to substantial improvements in patient outcomes. However, limitations related to accessibility, treatment costs, manufacturing complexity, and toxicity management continue to restrict their widespread use. As a result, there remains a pressing need for innovative therapies that combine efficacy, safety, and broad clinical applicability.

As part of its special ASCO 2026 coverage series, “China Perspectives at ASCO,” Oncology Frontier – Hematology Frontier invited leading Chinese experts to interpret the most practice-changing research presented at this year’s meeting and discuss its relevance to clinical practice in China.

Despite significant advances in recent years, the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) continues to present major clinical challenges. Existing therapies offer limited efficacy for many patients, particularly those with high-risk disease, highlighting a substantial unmet medical need.

The treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a major clinical challenge. While CAR-T cell therapy can induce rapid and deep remissions, many patients continue to face a substantial risk of relapse. Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy has emerged as a promising curative strategy. However, evidence regarding its long-term efficacy, optimal timing, and the role of molecular biomarkers in guiding treatment decisions has remained limited.

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is currently underway in Chicago, bringing together oncology experts from around the world to showcase the latest advances in cancer research and treatment.

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is currently underway in Chicago, bringing together oncology experts from around the world to showcase the latest advances in cancer research and treatment.